60 DEGREES PHARMACEUTICALS, INC. 2026: Revenue $207.9K, EPS ($0.9) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.60 DEGREES PHARMACEUTICALS reported Q2 2026 results with revenue of $207.9K, up 106% YoY, and a diluted loss per share of ($0.9), improving from ($5.01) in the prior year. The company achieved Nasdaq compliance via a reverse stock split, expanded partnerships including Runway Health and GoodRx, and ramped R&D for babesiosis trials.
60 DEGREES PHARMACEUTICALS, INC. reported results for the quarter ended 2026 with revenue of $207.9K, a net loss of ($2.4M), and diluted loss per share of ($0.9), compared with revenue of $100.93K, a net loss of ($1.84M) and diluted loss per share of ($5.01) in the prior-year quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $207.9K | $100.93K | 106% |
| Net income² | ($2.4M) | ($1.84M) | (30%) |
| Diluted EPS³ | ($0.9) | ($5.01) | 82% |
¹ Reported as “Product Revenues – net of Discounts and Rebates”. ² Reported as “Net Loss - attributed to common stockholders”. ³ Reported as “Diluted loss per Common Share (1)”.
Business Highlights
- Revenue growth: Product revenue rose 40% year-to-date to $370K, driven by increased shipments to third-party logistics providers despite flat pharmacy sell-through.
- Channel shift: 3PL concentration increased to about 92% of U.S. net sales as Infuserve resumed purchasing via 3PL.
- Access and partnerships: Expanded patient access through a Runway Health partnership and launched a GoodRx program in February 2026.
- Corporate and operational milestones: Completed a 1-for-4 reverse stock split, regained Nasdaq compliance, and signed an FSU patent license for an Australian Chestnut extract.
- Clinical and R&D activity: Ramped R&D with three active babesiosis trials and higher trial-related spending to support tafenoquine programs.
Original SEC Filing: 60 DEGREES PHARMACEUTICALS, INC. [ SXTP ] - 10-Q - Aug. 14, 2026